Actinium-225 (²²⁵Ac)

A promising alpha-emitting isotope for targeted cancer therapy, particularly in treating metastatic prostate cancer and neuroendocrine tumors. Medicare Russia ensures reliable production and supply for clinical and research applications.

Availability Production status of isotope, categorized under one of the following:
R&D stage.

For more details please contact: export@mdcr.ru